MedPath

Cochlear*s Direct Acoustic Cochlear Stimulator Investigational Device (C-DACS ID) clinical trial CAG5229

Phase 2
Completed
Conditions
fixation of the stapes
Otosclerosis
10019243
Registration Number
NL-OMON34163
Lead Sponsor
Cochlear AG
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
5
Inclusion Criteria

1. Eighteen years of age or older
2. Mixed severe to profound hearing loss
3. Conductive hearing loss is a result of otosclerosis or prior failed stapes surgery
4. Bone conduction thresholds are worse than 40 dB HL on at least 3 out of 5 frequencies (500 Hz, 1 kHz, 2 kHz, 3 kHz and 4 kHz) but must be measurable at all five frequencies
5. Bone conduction thresholds equal to or greater than 30 dB HL in all frequencies
6. Air-bone gap equal to or greater than 30 dB HL on at least 3 out of 5 frequencies
7. Bone conduction of contra-lateral ear is equal to or worse than 30 dB HL at the best frequency

Exclusion Criteria

1. Participation in another medical device study
2. Unwillingness or inability of the subject to comply with all study requirements
3. Bone conduction threshold exceeds 80 dB HL at 1 or more out of 5 frequencies (500 Hz, 1 kHz, 2 kHz, 3 kHz and 4 kHz)
4. Air conduction threshold exceeds 120 dB HL at 1 or more out of 5 frequencies
(500 Hz, 1 kHz, 2 kHz, 3 kHz and 4 kHz)
5. Medical or psychological conditions that would contraindicate undergoing surgery
6. Sudden hearing loss
7. Disabling tinnitus
8. Insufficient mastoid and/or ear canal size (to be checked on CT scan)
9. Other criteria at investigator*s discretion

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Audiological: aided free field hearing thresholds and scores of speech<br /><br>discrimination.<br /><br>Chirurgisch: complication registration and bone conduction thresholds.<br /><br>The subjective experiences of the participants will be tested by the APHAB<br /><br>questionnaire. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>nvt</p><br>
© Copyright 2025. All Rights Reserved by MedPath